Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (7961)	11/13/2000 12:22:26 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 8116

Cytogen Corp. - Princeton, N.J. 3rd Quar Sept. 30: 2000 1999 Revenue $2,519,000 $2,346,000 Net income a (16,663,000) (1,232,000) Avg shrs 73,632,000 68,757,000 Shr earns Net income a (.23) (.02) Figures in parentheses are losses. a. Includes a nonrecurring charge of $13.1 million, or 18 cents a share, related to the acquisition of marketing rights for two products. Excluding this, the company lost $3.4 million, or 5 cents a share. Cytogen Corp.'s (CYTO) third quarter product sales rose to $1.98 million from $1.83 million a year earlier. Royalty revenue increased to $523,000 from $245,000 last year, while license and contract revenue fell to $17,000 from $267,000 in the year-ago quarter. Cytogen signed a binding letter of intent to market and distribute Draxis Health Inc.'s (DRAX) prostate cancer therapy BrachySeed in the U.S. Cytogen and Draxis are in talks for a definitive marketing and distribution agreement. The company expects to launch BrachySeed by the end of the year. Cytogen, a biopharmaceutical company, said recent studies suggest that radioimmuno-guided brachytherapy can be successfully combined with the company's existing ProstaScint therapy.